Boston University, Department of Biomedical Engineering, Boston, MA, United States of America; Ionic Pharmaceuticals, LLC, Brookline, MA, United States of America.
Massachusetts General Hospital, Boston, MA, United States of America.
J Control Release. 2021 Sep 10;337:144-154. doi: 10.1016/j.jconrel.2021.07.012. Epub 2021 Jul 16.
One of the foremost challenges in translating nanoparticle technologies to the clinic is the requirement to produce materials on a large-scale. Scaling nanoparticle production methods is often non-trivial, and the success of these endeavors is frequently governed by whether or not an intermediate level of production, i.e., "pilot-scale" production, can be achieved. Pilot-scale production at the one-liter scale serves as a proof-of-concept that large-scale production will be possible. Here, we describe the pilot-scale production of the expansile nanoparticle (eNP) technology including verification of activity and efficacy following scaleup. We describe the challenges of sonication-based emulsification procedures and how these were overcome by use of a Microfluidizer technology. We also describe the problem-solving process that led to pre-polymerization of the nanoparticle polymer-a fundamental change from the lab-scale and previously published methods. Furthermore, we demonstrate good control over particle diameter, polydispersity and drug loading and the ability to sterilize the particles via filtration using this method. To facilitate long-term storage of these larger quantities of particles, we investigated six lyoprotectants and determined that sucrose is the most compatible with the current system. Lastly, we demonstrate that these changes to the manufacturing method do not adversely affect the swelling functionality of the particles, their highly specific localization to tumors, their non-toxicity in vivo or their efficacy in treating established intraperitoneal mesothelioma xenografts.
将纳米颗粒技术转化为临床应用面临的首要挑战之一是需要大规模生产材料。扩大纳米颗粒生产方法的规模通常并不容易,这些努力的成功与否通常取决于是否可以实现中间规模的生产,即“中试规模”生产。在 1 升规模上进行中试生产是证明大规模生产可行的概念验证。在这里,我们描述了可膨胀纳米颗粒(eNP)技术的中试生产,包括在扩大规模后验证其活性和功效。我们描述了基于超声乳化的乳化程序的挑战,以及如何通过使用微流化器技术克服这些挑战。我们还描述了导致纳米颗粒聚合物预聚合的问题解决过程,这是从实验室规模和以前发表的方法的根本改变。此外,我们证明了通过这种方法可以很好地控制粒径、多分散性和载药量,并能够对颗粒进行过滤消毒。为了便于长期储存这些大量颗粒,我们研究了六种冷冻保护剂,并确定蔗糖与当前系统最兼容。最后,我们证明了这些制造方法的改变不会对颗粒的膨胀功能、其对肿瘤的高度特异性定位、其体内的非毒性或其治疗已建立的腹膜间皮瘤异种移植物的功效产生不利影响。